Insight

Kinetic Profiling

Sep 6, 2024, 09:54

Kinetic Profiling of RAS Mutations With Circulating Tumor DNA Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient

JCO Precision Oncology made the following post on X:

“Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient.”

Authors: Florence T.H. Wu, James T. Topham, Chris J. O’Callaghan, Harriet Feilotter, Hagen F. Kennecke, Leylah Drusbosky, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Eric X. Chen, Jonathan M. Loree.

Source: JCO Precision Oncology/X

Canadian Cancer Trials Group CO.26 Trial cancer Chris J. O'Callaghan Circulating tumor DNA Daniel J Renouf Derek J. Jonker Dongsheng Tu Eric X. Chen Florence T.H. Wu Hagen F.Kennecke Harriet Feilotter James T. Topham Jonathan M. Loree Leylah Drusbosky Metastatic colorectal cancer OncoDaily Oncology RAS mutations

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage